Affimed (NASDAQ:AFMD) Receives $45.00 Average PT from Analysts

Shares of Affimed (NASDAQ:AFMD) have been assigned an average recommendation of “Buy” from the five brokerages that are covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $45.00.

AFMD has been the topic of a number of research analyst reports. Wells Fargo & Company reduced their price target on shares of Affimed from $30.00 to $25.00 and set an “overweight” rating on the stock in a research note on Monday, April 1st. StockNews.com started coverage on shares of Affimed in a research note on Tuesday, January 2nd. They set a “sell” rating on the stock. HC Wainwright upped their target price on shares of Affimed to $10.00 and gave the stock a “buy” rating in a research note on Monday, April 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a research note on Monday, April 1st.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in AFMD. Advisor Group Holdings Inc. grew its holdings in Affimed by 258.3% during the 1st quarter. Advisor Group Holdings Inc. now owns 8,967 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 6,464 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Affimed by 23.9% during the 1st quarter. JPMorgan Chase & Co. now owns 68,895 shares of the biopharmaceutical company’s stock worth $301,000 after acquiring an additional 13,300 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Affimed by 1.9% during the 1st quarter. Bank of New York Mellon Corp now owns 302,737 shares of the biopharmaceutical company’s stock worth $1,323,000 after acquiring an additional 5,513 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in Affimed during the 1st quarter worth approximately $726,000. Finally, Vanguard Group Inc. grew its holdings in Affimed by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 1,386,701 shares of the biopharmaceutical company’s stock worth $6,060,000 after acquiring an additional 5,499 shares in the last quarter. Institutional investors and hedge funds own 30.82% of the company’s stock.

Affimed Price Performance

Affimed stock opened at $5.23 on Thursday. The company’s 50 day simple moving average is $5.55 and its 200-day simple moving average is $5.00. The company has a market capitalization of $79.65 million, a price-to-earnings ratio of -0.62 and a beta of 2.05. Affimed has a 1 year low of $2.23 and a 1 year high of $11.10. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.23 and a current ratio of 3.25.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.